Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Recruiting · NCT07143669
Conditions: Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
At a glance
- Research payments reported, 2025
- $10,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 750
About the trial
- Sponsor
- Blueprint Medicines Corporation
- Tested
- Screening (other)
- Dates
- Started 2025-10-17; completion 2028-10-31
- Results posted
- Not yet
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
From ClinicalTrials.gov, last updated 2026-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $10,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Care Access Research Llc $10,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.